Background-More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association. Methods and Results-A multivariate logistic regression model was used to identify baseline predictors of stroke in 4038 patients with diabetes mellitus, chronic kidney disease, and anemia randomized to receive darbepoetin alfa or placebo.
T he presence of anemia has been consistently associated with a higher risk of cardiovascular (CV) events in adjusted analyses from both epidemiological observations and clinical trials encompassing broad and diverse populations. [1] [2] [3] [4] [5] [6] [7] Among patients with type 2 diabetes mellitus and nondialysis chronic kidney disease (CKD), those with anemia had a Ϸ60% to 90% greater adjusted relative risk of death, myocardial infarction, or stroke in a pooled analysis of 4 major epidemiological cohorts. 8 However, in the placebocontrolled Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), 9 correction of anemia in patients with type 2 diabetes mellitus and nondialysis CKD with the erythropoiesis-stimulating agent (ESA) darbepoetin alfa had no effect, overall, on the composite end point of death or nonfatal CV events. Moreover, we observed a statistically significant and clinically important increase in the rate of stroke in patients assigned to darbepoetin alfa.
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To aid clinical decision making in prescribing ESA therapy, we examined baseline characteristics and postrandomization factors, including blood pressure, platelet count, achieved hemoglobin level, and treatment dose, which might explain the heightened risk of stroke associated with darbepoetin alfa.
Methods
The Trial to Reduce Cardiovascular Events With Aranesp Therapy was a randomized, double-blind, placebo-controlled trial of patients with type 2 diabetes mellitus, nondialysis CKD (estimated glomerular filtration rate [eGFR] of 20 -60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ) and anemia (hemoglobin level Յ11 g/dL) designed to determine whether treatment with darbepoetin alfa would reduce the risk of (1) a cardiovascular composite of death, myocardial infarction, heart failure, stroke, or hospitalization for myocardial ischemia, (2) a renal composite of death or end-stage renal disease (initiation of dialysis), or both. Subjects were randomly assigned to receive either darbepoetin alfa to attempt to achieve a hemoglobin level of 13 g/dL or placebo with rescue darbepoetin alfa if their hemoglobin level was Ͻ9 g/dL. Hemoglobin levels and vital signs were assessed every 2 weeks during the titration period and monthly thereafter. The rationale and design, 10 baseline characteristics, 11 and the primary results 9 of the trial have been published. The Trial to Reduce Cardiovascular Events With Aranesp Therapy is registered at http://www.clinicaltrials.gov, unique identifier: NCT00093015. The randomization groups were similar without any clinically meaningful baseline differences except for history of heart failure, which was more prevalent in the placebo arm.
All potential end points, including stroke, were prospectively defined and adjudicated by a central committee that was blinded to treatment assignment and hemoglobin levels. Stroke was defined as a focal neurological deficit of sudden onset lasting Ͼ24 hours or resulting in death and which was not due to another readily identifiable cause (ie, brain tumor or trauma). Neuroimaging was not mandated by protocol and performed as deemed necessary for clinical reasons. Where available, imaging reports were used to categorize stroke as hemorrhagic or nonhemorrhagic (cases without imaging results were considered as nonhemorrhagic strokes). For patients who experienced Ͼ1 stroke, only the first stroke was used in this analysis.
Statistical Analysis
Distributions of baseline characteristics are presented as median (interquartile range) for the overall population. In this posthoc analysis, univariate comparisons for baseline characteristics between patients who experienced a stroke and those who did not were performed with 2-sample Wilcoxon rank-sum test or the Fisher exact test. History of cardiovascular diseases was derived from the clinical database as previously used and a history of stroke or transient ischemic attack was part of the definition of history of cardiovascular diseases. 9 The urinary protein-to-creatinine ratio was log transformed. The cumulative incidence function of stroke was presented by treatment arm and history of stroke, and the treatment effect was estimated using a proportional subdistribution hazards approach. 12 Potential baseline predictors of stroke were selected on the basis of clinically known risk factors for stroke as well as factors identified in the univariate analysis. Logistic regression was used for outcomes analysis. A stepwise forward selection procedure (PϽ0.10) was performed to help build a multivariable model. Variables considered clinically relevant that were not statistically significant were retained in the model. In addition, interaction among treatment allocation and statistically significant baseline variables was prospectively evaluated.
To assess whether the increased risk of stroke in patients treated with darbepoetin alfa could be explained by postrandomization factors, we conducted a nested-case control analysis within each treatment arm. Using the baseline variables selected in the logistic regression model, a propensity score for stroke was developed within each treatment arm separately to select subjects, free of stroke by the end of the trial, who would serve as controls. Within each treatment arm, every patient experiencing a stroke (case) was matched to 10 controls that had an equivalent duration of follow-up (1:10 nearest neighbor propensity-score matching). Postrandomization factors studied included hemoglobin level, blood pressure, platelet count, and dose of darbepoetin alfa. For each factor, we compared the latest value available in the 3 months preceding the stroke (or equivalent parallel period for controls) between cases and controls in each treatment arm separately using generalized Hodges-Lehmann median difference test for clustered data. 13 In additional sensitivity analyses, we compared the average of the latest available values (up until the stroke or the equivalent period for controls), the highest value in the latest 3 months, and highest during entire follow-up. We also varied the case-control ratio (1:1, 1:5, and 1:15). A P value of Ͻ0.05 was considered statistically significant. All analyses were performed with Stata 11.1 (StataCorp, College Station, TX), and R 2.10.2 (R Project for Statistical Computing, Vienna, Austria).
Results
Over a median follow-up period of 29.1 months, 154/4038 (3.8%) of patients randomized had a stroke, 53/2026 (2.6%, 1.1 per 100 patient-years) in the placebo arm and 101/2012 (5.0%, 2.1 per 100 patient-years) in the darbepoetin alfa arm; hazard ratio 1.92, 95% confidence interval, 1.38 to 2.68. Of the total of 154 strokes, 133 (86.4%) were categorized as nonhemorrhagic (ischemic cause: 112 [72.7%]; unknown: 21 [13.6%]) and 21 (13.6%) as hemorrhagic. Each type of stroke was numerically more frequent in the darbepoetin alfa group compared with the placebo group: nonhemorrhagic, 87 (4.3%) versus 46 (2.3%), and hemorrhagic, 14 (0.7%) versus 7 (0.3%), respectively.
Baseline Predictors of Stroke
In addition to treatment assignment to darbepoetin alfa, univariate predictors of stroke included history of cardiovascular diseases, specifically history of stroke, or transient ischemic attack. Although a history of stroke or transient ischemic attack was part of the definition of history of cardiovascular diseases, both remained statistically significantly associated with incident stroke during follow-up. Patients who had a stroke during the trial also had higher urinary protein-to-creatinine ratio and glycohemoglobin and lower body mass index (BMI), eGFR, serum albumin, hemoglobin, and transferrin saturation. Imbalances in baseline medication use were also found, with stroke patients more likely to be on a vitamin K antagonists or insulin and less likely to be on an oral hypoglycemic agent (Table 1) . In a multivariate logistic regression model of predictors of stroke (Table 2) , the 2 predictors with the highest z score were assignment to darbepoetin alfa therapy (odds ratio 2.08; 95% confidence interval, 1.47-2.94), and a history of stroke or transient ischemic attack (odds ratio 2.00; 95% confidence interval, 1.36 -2.94). Other independent baseline predictors included urinary protein-to-creatinine ratio, insulin therapy, history of CV disease, and lower serum hemoglobin level or BMI.
We tested whether any of the independent baseline predictors of stroke modified the risk of this event related to treatment with darbepoetin alfa. None of the interaction tests were statistically significant (all were PϾ0.1). In particular, although the darbepoetin alfa-related risk of stroke was higher in patients with prior stroke (HR 2.99; 95% confidence interval, 1.40 -6.36) than in those without prior stroke (HR 1.61; 95% confidence interval, 1.14 -2.41), the test for interaction was not significant (Pϭ0.25, the Figure) . OR indicates odds ratio; CI, confidence interval; TIA, transient ischemic attack; CV, cardiovascular; Hb, hemoglobin; BMI, body mass index; bpm, beats per minute; eGFR, estimated glomerular filtration rate; and SBP, systolic blood pressure.
Variables not retained in multivariate model that were significant in univariate analyses: serum albumin, glycated hemoglobin, and transferrin saturation.
Figure.
Cumulative incidence function of stroke by treatment arm and history of stroke. HR indicates hazard ratio.
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In a treatment-stratified, nested, case-control analysis, there was no difference between patients who experienced a stroke and those who did not in terms of latest blood pressure value, hemoglobin level, platelet count, or dose of darbepoetin alfa (Table 3) . Among patients assigned to darbepoetin alfa experiencing a stroke (nϭ86), the last-measured blood pressure in the 90 days preceding the event was 135/72 mm Hg compared with 134/72 mm Hg over the same time interval in patients who did not have a stroke (nϭ923; PϾ0.50). In patients in the darbepoetin alfa-treated group experiencing a stroke, the last-measured hemoglobin concentration in the 90 days preceding stroke was 12.3 mg/dL compared with 12.5 mg/dL in darbepoetin alfa-treated patients without a stroke (Pϭ0.09).
In the placebo-treated group, there were also no differences in any of the evaluated factors between those with and without a stroke (Table 3) . Moreover, the proportion of patients receiving rescue treatment with darbepoetin alfa was not different between cases with strokes and their nonstroke controls (14% versus 19%, Pϭ0.54; Table 3 ). Postrandomization iron parameters also did not significantly differ between subjects with and without stroke. Within each treatment arm, the latest ferritin and transferrin saturation values preceding a stroke event were similar among cases and controls. The number of subjects being treated with intravenous iron preceding the event was similar among cases and controls ( Additional sensitivity analyses examining the latest, highest, and average value of blood pressure, hemoglobin, platelet count, and dose of darbepoetin alfa in the 90 days preceding the event (or during the entire follow-up) each produced similar results, as did varying the case-to-control ratio. In each analysis, the postrandomization blood pressure, hemoglobin level, platelet count, and dose of darbepoetin alfa were similar between the cases with a stroke and their nonstroke controls (see online-only Data Supplement).
Discussion
We found that in this cohort of patients with type 2 diabetes mellitus, nondialysis CKD, and anemia, allocation to darbepoetin alfa was associated with a statistically significant doubling of the risk of stroke. The risk of stroke related to darbepoetin alfa did not appear to be associated with any baseline characteristic. Furthermore, this risk was not mediated by postrandomization factors previously implicated as mechanisms of ESA-related adverse outcomes, 14, 15 including increase in hemoglobin level, blood pressure, or platelet number, and was not related to dose of darbepoetin alfa.
Although a number of baseline characteristics predicted risk of stroke in the overall TREAT population, none of these modified the risk of stroke related to darbepoetin alfa. In particular, history of stroke did not modify the risk related to darbepoetin (ie, the risk of stroke with this ESA was increased both in patients with and without a prior history of stroke). Interestingly, we observed an inverse relationship between BMI and risk of stroke where subjects with lower BMI at baseline were at higher risk of stroke. This association was recently described in a cohort of subjects with diabetes mellitus 16 and may carry important prognostic information, given that lower BMI at the time of stroke was also associated with a higher risk of death. 17 Of the postrandomization variables examined, increase in hemoglobin has most often been proposed as a mediator of ESA-related CV risk, in part because it raises blood viscosity and vascular resistance and may increase blood pressure. 15, 18 The initial rapid rise in hemoglobin concentration, the socalled ramp phase, has been of particular concern. 19 However, we did not find any association between stroke and average achieved hemoglobin, change in hemoglobin, or peak hemoglobin during varying follow-up periods in either darbepoetin alfa-treated or placebo-treated patients. In fact, the achieved hemoglobin level was lower in the stroke cases than in the nonstroke controls although this difference was not statistically significant. Furthermore, there was a marked temporal disassociation between the early rise in hemoglobin and the late augmentation in stroke rates, 9 which does not support concerns about the ramp phase of treatment. 19 Although earlier studies in patients with severe anemia suggested that blood pressure may increase in up to one third of patients treated with recombinant human erythropoietin, there was no difference in systolic blood pressure between the treatment groups in TREAT, and a 1.7-mm Hg difference in diastolic pressure was observed (higher in the darbepoetin alfa arm). 9 More importantly, in the present analysis, there was no association between postrandomization blood pressure and the incidence of stroke despite extensive analyses. Specifically, the latest systolic or diastolic pressure preceding stroke in cases (or during the equivalent period in nonstroke controls) was not different between cases and controls within each treatment arm. The same was true for mean and highest pressures measured preceding stroke or at any time during the entire follow-up period. In addition, as previously reported, there was no statistically significant difference between treatment groups in reporting of hypertension as an adverse event by investigators: 24.4% in patients randomized to darbepoetin alfa compared with 22.0% in those assigned to placebo (Pϭ0.07). 9 Increases in platelet count, reactivity, or both may also occur after ESA administration, and could promote a prothrombotic milieu. 20 In patients undergoing dialysis in the Normal-Hematocrit study, the risk of thrombosis affecting the vascular access site was increased in the higher-hemoglobin target group compared with the lower-hemoglobin target group: 243 patients (39%) versus 176 patients (29%), Pϭ0.001. 21 In TREAT, thromboembolic events were also reported more frequently in patients treated with darbepoetin alfa compared with placebo (venous: 2.0% versus 1.1%, Pϭ0.02; arterial: 8.9% versus 7.1%, Pϭ0.04). 9 In the current analyses, however, there was no association between various assessments of platelet count and incident stroke in either treatment arm. Dose-related nonerythropoietic toxicity has also been invoked as a possible mechanism for ESA-related risk. 22 In the German Multicenter Erythropoietin Stroke Trial, there was an increase in mortality among acute-stroke patients randomized to just 3 doses of epoetin alfa given over 48 hours. 23 In TREAT, the median monthly dose of darbepoetin alfa administered to patients who had a stroke was not different than the dose administered to the matched nonstroke controls. Furthermore, in the placebo arm, there was no relation between the risk of stroke and use of darbepoetin alfa as rescue therapy. We have also reported that poor initial hemoglobin response to an ESA (despite escalating dosing) was associated with increased risk of death or cardiovascular events in TREAT. 24 However, the rate of stroke was not higher in patients with a poor initial hemoglobin response to darbepoetin alfa therapy.
Some limitations of this analysis need to be acknowledged. The increase in stroke with darbepoetin alfa could be a chance finding. However, the similar observation in the study by Parfrey and colleagues 25 and the relatively large number of strokes in TREAT argue against this. Furthermore, given the clinical importance of stroke, it is safer to adopt a conservative approach and assume this increased risk to be actual. 26 Subtle differences in blood pressure between treatment groups might have been detected using more intensive methods such as ambulatory monitoring. Greater modification of antihypertensive medication in the darbepoetin alfa group by investigators might also have concealed an increase in blood pressure in the treatment group compared with placebo. Although platelet count did not differ between treatments, darbepoetin alfa might have changed platelet reactivity, which was not measured. Although we did not have complete or comprehensive imaging data on stroke type or information on stroke severity and outcome, this end point was prospectively defined and centrally adjudicated without knowledge of randomization arm or hemoglobin levels.
In summary, darbepoetin alfa doubled the risk of stroke in patients with type 2 diabetes mellitus, nondialysis CKD, and anemia. No baseline characteristic was associated with darbepoetin alfa-related risk of stroke. Similarly, despite extensive analyses of postrandomization blood pressure, hemoglobin, platelet count, and dose of treatment, no factor previously identified as a potential mechanism for ESA-related cardiovascular risk explained the increase in risk of stroke observed with darbepoetin alfa. Measurement of these readily available follow-up parameters cannot be used to mitigate the risk of darbepoetin alfa-related stroke.
Sources of Funding
The TREAT trial was supported by Amgen. This analysis was conducted independently by the academic coauthors using the TREAT database at the Brigham and Women's Hospital, Boston, MA. 
Disclosures

